Option chain shows key data for Pharvaris's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Pharvaris.

Pharvaris (NASDAQ:PHVS) Stock, Option Chain

Pharvaris

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .

PHVS

Biotech

News

Health Care

General

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment.

FDA Clears Pharvaris&#39; Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

MLGO

OPTN

SERA

YEXT

U.S. stocks traded mixed toward the end of trading on Wednesday.

The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&amp;P 500 also fell, dropping, 0.05% to 4,564.73.

Gold Moves Higher; Campbell Soup Earnings Top Expectations

Movers

AAOI

ALLR

ARVN

ASAN

ASPN

AVAV

BCRX

CANO

CHSN

CJET

CLIN

CZOO

FLNC

GBNH

JNVR

LEJU

LGHL

LOVE

MESA

NRSN

NVNI

PHIO

PLAY

POWL

RELI

RENT

SFIX

SOAR

TGTX

WBUY

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pharvaris NV

Guggenheim analyst Robert Drbul maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Buy and lowers the price target from $180 to $145.

Price Target

Analyst Ratings

Guggenheim Maintains Buy on Target, Lowers Price Target to $145

Raymond James analyst John Freeman maintains Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) with a Outperform and raises the price target from $58 to $62.

VNOM

Raymond James Maintains Outperform on Viper Energy, Raises Price Target to $62

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Launches Meal Replacement Bars And Shakes To Enhance Personalized Weight Loss Plans, Offering Comprehensive Nutrition Support For Customers Starting At $110/Month

Agrify Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) announced Thursday that is has secured a $25.9 million non-brokered private placement.
<h3 class="wp-block-heading">What Happened</h3>
The company said it has entered into securities purchase agreements with institutional and accredited investors in a non-brokered private placement priced at $22.30 per share.
The placement is set to close on Thursday, Nov. 21, subject to customary closing conditions.
Benjamin Kovler, chairman and interim CEO, participated in the private placement to purchase 10,000 shares of common stock at $38.76.
The news comes on the heels of the company's board of directors having <a href="https://www.benzinga.com/markets/cannabis/24/11/41760263/marijuana-growing-solution-provider-agrify-gets-20m-boost-from-green-thumb-to-power-up-cannabis-">approved</a> a $20 million convertible secured note. Of that sum $10 million will be drawn upon at closing, from a wholly-owned subsidiary of Green Thumb Industries Inc., Agrify said in a press release.
Before this, the Green Thumb subsidiary acquired an ownership stake in Agrify through the purchase of common stock and warrants from its outgoing chairman and CEO Raymond Chang and outgoing director I-Tseng Jenny Chan.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38876948/cannabis-cultivation-solutions-provider-agrify-and-californias-natures-miracle-sign-definitive-m">Cannabis Cultivation Solutions Provider Agrify And California&#8217;s Nature&#8217;s Miracle Sign Definitive Merger Deal</a>
<h3 class="wp-block-heading">Why It Matters</h3>
Agrify plans to use the proceeds from the private placement for general corporate purposes, including, among other things, working capital and business development. It intends to allocate capital to opportunities in the cannabis and hemp industries.
"This funding is a strong move for Agrify and our shareholders as we were able to raise approximately $26 million in a non-brokered deal (gross equals net)," Kovler said. "We plan to allocate this capital into opportunities within our circle of competence to benefit stockholders. We are excited about the opportunity set and current consumer trends in cannabis and hemp. The team continues to work hard to close the previously announced Señorita transaction, and it remains on track for closing at or around year-end."
Agrify reported its third quarter 2024 financial results on Nov. 14, revealing a $1.9 million revenue, down from $3.1 million a year ago. The company posted a net loss of $18.6 million, largely driven by a $15 million change in the <a href="https://www.benzinga.com/news/earnings/24/11/41998220/agrifys-q3-revenue-drop-18-6m-loss-amid-new-leadership">fair value of warrant liabilities.</a>
<h3 class="wp-block-heading">AGFY Price Action</h3>
Agrify's shares traded 25.15% lower at $29.01 per share at the time of writing on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39271387/cannabis-cultivation-solutions-provider-agrify-announces-500k-turnkey-extraction-equipment-deal-">Cannabis Cultivation Solutions Provider Agrify Announces $500K Turnkey Extraction Equipment Deal With This NJ Co.</a></li>
</ul>

Cannabis

Financing

AGFY

NASDAQ-Traded Cannabis Co. Agrify Secures $25.9M Via Private Placement, Here's How They'll Spend It

Guggenheim analyst Joseph Osha maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Buy and lowers the price target from $8 to $7.

SHLS

Guggenheim Maintains Buy on Shoals Technologies Gr, Lowers Price Target to $7

Raymond James analyst Brian Peterson maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Outperform and raises the price target from $41 to $55.

GLBE

Raymond James Maintains Outperform on Global E Online, Raises Price Target to $55

U.S. natural gas prices are on fire this month, surging by about 50% to reach $3.40 per million British thermal units as of Nov. 21, the highest level <a href="https://www.benzinga.com/24/11/42113449/natural-gas-prices-spike-to-over-1-year-highs-oil-surges-to-70-as-russia-fires-intercontinental-ballistic-missile-to-ukraine">in over a year.</a>
November is poised to mark the strongest surge in natural gas at the Henry Hub pricing point since July 2022, fueled by heightened geopolitical tensions, unseasonably cold U.S. weather and rising export demand.
For investors, this sharp price rebound has cast a spotlight on natural gas stocks poised to benefit from the renewed momentum in the natural gas markets.
<h1 class="wp-block-heading">Why Are Natural Gas Prices Spiking?</h1>
The price rally has been driven by a combination of factors:
<ul>
<li>Plunging Temperatures Across the U.S.: After a relatively warmer-than-average start to the winter, the situation has drastically changed over the past few weeks. The National Oceanic and Atmospheric Administration forecasts the first major snowfall of the season for parts of the central and northern Appalachians, with lower elevations in Pennsylvania and New York also bracing for accumulation. This colder weather has pushed demand for heating sharply higher.</li>
<li>Geopolitical Tensions Between Russia and Ukraine: Russia's launch of an intercontinental ballistic missile on Thursday, combined with Ukraine&#8217;s recent use of Western-made missiles to target Russian territory, has added a geopolitical risk premium to natural gas markets.</li>
<li>Supply Concerns in Europe: Austria&#8217;s OMV Group revealed earlier this month that it will stop receiving natural gas volumes from Russia&#8217;s Gazprom, reigniting fears of winter supply shortages in Europe and potentially shifting demand to the U.S. for liquefied natural gas (LNG) exports.</li>
</ul>
<h1 class="wp-block-heading">7 Natural Gas Stocks Benefiting From The Rally</h1>
As natural gas prices rally, several U.S. energy companies stand to gain from higher commodity prices and increased demand. Here are seven stocks to watch:
<h4 class="wp-block-heading">1. EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</h4>
EQT is the largest natural gas producer in the U.S., with operations in the Appalachian Basin. The company benefits directly from higher domestic gas prices.
Shares of EQT Corp. are up 30% month-to-date, on track for their strongest performing month since March 2022. 
<h4 class="wp-block-heading">2. ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>)</h4>
As a midstream operator, ONEOK processes and transports natural gas, profiting from higher pipeline volumes as demand increases.
Shares of ONEOK Inc. are up 19.6% in November, eyeing their best monthly performance since November 2020. 
<h4 class="wp-block-heading">3. Targa Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>)</h4>
Targa specializes in natural gas gathering and processing, positioning it to benefit from both domestic demand and export growth.
Targa shares have rallied 24% this month, on track to notch the 10th straight positive month and the strongest one in four years.
<h4 class="wp-block-heading">4. Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</h4>
One of the largest pipeline operators in the U.S., Kinder Morgan&#8217;s infrastructure is critical for natural gas transportation across regions.
Kinder Morgan has seen its stock rally 16% in November, potentially positioned for the best month since November 2020. 
<h4 class="wp-block-heading">5. Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>)</h4>
Focused on natural gas and liquids production, Antero Resources has significant exposure to the Appalachia region, where colder weather is driving demand.
Shares of Antero Resources have soared 32% month-to-date, following a 9.7% drop in October. 
<h4 class="wp-block-heading">6. Cheniere Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>)</h4>
As the top exporter of liquefied natural gas from the U.S., Cheniere benefits from global demand for natural gas, particularly in Europe.
Cheniere Energy has gained 16% thus far this month. 
<h4 class="wp-block-heading">7. Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>)</h4>
Williams operates natural gas infrastructure and transmission pipelines, playing a vital role in connecting supply to end markets.
Shares are up 13.6% in November, following a 14.7% surge in October. 
<h1 class="wp-block-heading">Chart: US Natural Gas Stocks Rallied In November</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21105956/image-221-1024x501.png" alt="" class="wp-image-659155" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21105956/image-221-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21105956/image-221-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21105956/image-221-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21105956/image-221-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21105956/image-221.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h1 class="wp-block-heading">EIA Natural Gas Outlook: Winter Demand and LNG Exports To Support Prices</h1>
The EIA's latest Short-Term Energy Outlook (STEO) is bullish about near-term natural price gains, supported by robust winter demand and growing LNG exports.
With colder-than-expected weather forecasted for the season, the EIA has increased its consumption estimates, particularly in residential and commercial sectors where heating needs dominate. Residential and commercial demand is now expected to average 36 billion cubic feet per day (Bcf/d), representing a 4% increase from last winter.
In 2025, U.S. marketed natural gas production is projected to grow by 1%, with the Permian Basin leading the way with a 6% increase, followed by a 5% rise in output from the Eagle Ford region. 
The EIA anticipates Henry Hub natural gas prices — as tracked by the United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – to climb steadily in early 2025, averaging $2.80 per million British thermal units in the first quarter and $2.90/MMBtu for the entire year. This represents a significant 33% increase compared to the 2024 average of $2.20/MMBtu.
Liquefied natural gas exports are expected to play a critical role in driving demand next year, with exports projected to increase by nearly 2 Bcf/d in 2025. The growth in LNG capacity, coupled with sustained international demand, further strengthens the outlook for higher natural gas prices in the coming year.
<h1 class="wp-block-heading">Goldman Sachs Natural Gas Outlook: $4.00 Delayed Until 2026</h1>
Goldman Sachs offers a more cautious perspective on natural gas prices, citing delays in the construction and operation of new LNG export facilities across the Americas.
According to analyst Samantha Dart, these delays are expected to soften the trajectory of U.S. natural gas price increases and could hinder Europe's ability to replenish its gas storage levels for the 2025 season.
Goldman Sachs revised its 2025 Henry Hub price forecast downward to $3/MMBtu, from a previous estimate of $3.40/MMBtu.
The bank also pushed its projection for U.S. natural gas prices to hit $4/MMBtu to 2026, postponing it from the fourth quarter of 2025. 
The firm indicates that while slower U.S. LNG export growth might ease domestic price pressures temporarily, it poses challenges for Europe, which will have fewer LNG cargoes at its disposal to fill storage next summer. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42112078/international-criminal-court-issues-arrest-warrants-for-netanyahu-gallant">International Criminal Court Issues Arrest Warrants For Israeli Prime Minister Netanyahu, Gallant For War Crimes</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Mid Cap

Specialty ETFs

ETFs

TRGP

7 US Natural Gas Stocks To Watch As Henry Hub Prices Surge 50% In November

<a href="https://hntrbrk.com/breaking-roblox-faces-undisclosed-probes-by-sec-enforcement-and-ftc-amid-hindenburg-accusations-of-inflated-key-metrics-for-wall-street-and-a-pedophile-hellscape-for-kids/" title="https://hntrbrk.com/breaking-roblox-faces-undisclosed-probes-by-sec-enforcement-and-ftc-amid-hindenburg-accusations-of-inflated-key-metrics-for-wall-street-and-a-pedophile-hellscape-for-kids/">https://hntrbrk.com/breaking-roblox-faces-undisclosed-probes-by-sec-enforcement-and-ftc-amid-hindenburg-accusations-of-inflated-key-metrics-for-wall-street-and-a-pedophile-hellscape-for-kids/</a>

Short Sellers

RBLX

Watching Roblox; Shares See A Spike In Volume To The Downside, Traders Circulate Report From HunterBrook Research

WIIM

GOOG

GOOGL

Alphabet shares are trading lower after the U.S. Department of Justice demanded that Google divest its Chrome browser.

IGIC

International General Insurance shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $130 price target.

Transdigm shares are trading lower following a report from The Bear Cave

Raymond James analyst John Freeman maintains Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) with a Strong Buy and raises the price target from $19 to $20.

CRGY

Raymond James Maintains Strong Buy on Crescent Energy, Raises Price Target to $20

DT Midstream shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $90 to $115.

TD Cowen analyst J. Derrick Wood maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Hold and raises the price target from $290 to $340.

TD Cowen Maintains Hold on Salesforce, Raises Price Target to $340

Raymond James analyst John Freeman maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Strong Buy and raises the price target from $156 to $167.

Raymond James Maintains Strong Buy on EOG Resources, Raises Price Target to $167

On Thursday, Reddit, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) is facing service disruptions again. This outage stems from an HTTP error, <a target="_blank" href="https://techcrunch.com/2024/11/21/reddit-is-down-again/" rel="noreferrer noopener">as per</a> TechCrunch.
On Wednesday, Reddit experienced <a target="_blank" href="https://www.benzinga.com/24/11/42112567/reddit-resolves-major-service-disruption-heres-what-happened" rel="noreferrer noopener">an afternoon outage</a> that disrupted its services. The company resolved the issue later in the evening.
The reported issues on Thursday peaked at close to 72,000 at 10:05 am&nbsp;ET, as per <a target="_blank" href="https://downdetector.com/status/reddit/" rel="noreferrer noopener">Downdetector</a>.
According to Downdetector, around 44% of the reported issues were related to website malfunctions, 52% to the app, and 5% to server connections.
Reddit&#8217;s <a target="_blank" href="https://www.redditstatus.com/" rel="noreferrer noopener">status page</a> mentioned degraded performance for reddit.com and said it is currently investigating a problem with its site at 7:51 am PT (or 10:51 am ET).
The company claimed to have identified the issue and is implementing repairs at 8:15 am PT (or 11:15 am ET). At 8:19 am&nbsp;PT (or 11:19 am ET), the company notified that it had fixed the problem and had returned to regular operation.
Price Action:&nbsp;RDDT stock traded higher by 8.38% to $147.69 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42096308/werides-robotaxi-and-partnerships-are-key-growth-drivers-for-global-expansion-analyst" target="_blank" rel="noreferrer noopener">WeRide&#8217;s Robotaxi And Partnerships Are Key Growth Drivers For Global Expansion: Analyst</a></li>
</ul>
Photo via Shutterstock

Tech

Media

RDDT

Reddit Suffers Second Disruption In Two Days

Citron Research&#8217;s Andrew Left believes the run in shares of MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is not going to end well in the near term, and he&#8217;s putting his <a href="https://www.benzinga.com/topic/andrew-left">money where his mouth is</a>.
What To Know: Left on Thursday announced a new short position in software firm turned Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holding company MicroStrategy, despite <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38883691/exclusive-first-he-bet-against-gamestop-now-andrew-left-is-long-bitcoin-short-ether">remaining bullish</a> on the trajectory of Bitcoin.
&#8220;$MSTR's volume has completely detached from BTC fundamentals,&#8221; the short seller said in a <a href="https://x.com/CitronResearch/status/1859608654590202325">post</a> on X. 
Benzinga has reached out to MicroStrategy for comment. 
Left noted in the post that his firm was <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/11/18516934/citron-long-on-bitcoin-says-microstrategy-is-best-investment-route?utm_source=chatgpt.com">bullish on MicroStrategy in 2020</a> when the stock was trading below $250 per share on a pre-split basis. He predicted at the time that MicroStrategy shares could hit $700.
&#8220;Fast forward to today: $MSTR has skyrocketed to over $5,000 (adjusted) &#8230; while Citron remains bullish on Bitcoin, we've hedged with a short <a href="https://x.com/search?q=%24MSTR&amp;src=cashtag_click">$MSTR</a> position,&#8221; Left said. &#8220;Much respect to <a href="https://x.com/saylor">@saylor</a>, but even he must know <a href="https://x.com/search?q=%24MSTR&amp;src=cashtag_click">$MSTR</a> is overheated.&#8221;
From Earlier This Year: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38883691/exclusive-first-he-bet-against-gamestop-now-andrew-left-is-long-bitcoin-short-ether">EXCLUSIVE: First He Bet Against GameStop, Now Andrew Left Is &#8216;Long Bitcoin… Short Ether&#8217;</a>
Left isn&#8217;t alone in thinking the recent surge in MicroStrategy shares won&#8217;t last. Seabreeze Capital Partners&#8217; Doug Kass <a href="https://x.com/DougKass/status/1859611593186709725">announced</a> a short position in MicroStrategy from $533.78 Thursday morning. At the time of writing, Kass had already covered at least 75% of the initial short. He closed half of his short position at $468 and another quarter of his initial position at $429.10. 
MicroStrategy shares have accelerated to the upside in recent weeks as the company continues to execute on its strategy to accumulate billions of dollars of Bitcoin. The company announced plans at the end of October to raise $42 billion over the next three years to keep buying Bitcoin.
MicroStrategy held a total of 331,200 Bitcoin purchased at an average price of approximately $49,874 per&nbsp;coin as of Nov. 17.
MSTR Price Action: <a href="http://benzinga.com/quote/mstr">MicroStrategy shares</a> were trading above $540 in pre-market trading Thursday morning. The stock pulled back at the open and continued to move lower after Left announced his short position. MicroStrategy shares were up 0.8% at $477.95 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Ideas

$BTC

MSTR

Short Seller Andrew Left Targets MicroStrategy Stock As Hedge Against Bullish Bitcoin Bet: 'Completely Detached From BTC Fundamentals'

SOUN

SoundHound AI shares are trading higher. The company announced its Amelia AI agents have supported the handling of 100,000 customer calls for Apivia Courtage and reduced the number of inbound queries handled directly by a customer relations team by nearly 20%.

Raymond James analyst Daniel Tamayo maintains F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) with a Outperform and raises the price target from $17 to $19.

Raymond James Maintains Outperform on F N B, Raises Price Target to $19

TD Cowen analyst Ritu Baral maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $10 to $9.

SAGE

TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pharvaris (PHVS – Research Report), Silence Therap...

Analysts Conflicted on These Healthcare Names: Pharvaris (PHVS), Silence Therapeutics (SLN) and Stevanato Group (STVN)

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris (PHVS – Research Report) today and set a price target of $34.00. The compa...

Pharvaris (PHVS) Gets a Buy from Morgan Stanley

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $42.0...

Oppenheimer Sticks to Their Buy Rating for Pharvaris (PHVS)

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of ...

Pharvaris (PHVS) Receives a Buy from Morgan Stanley

Pharvaris (PHVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Schwartz from L...

Pharvaris's Promising Developments in HAE Treatment Drive Buy Rating

Pharvaris (PHVS) has released an update. Pharvaris, a biopharmaceutical company, reported a robust financial position with €305 million in cash, as...

Pharvaris Advances in HAE Treatment with Strong Financials

Pharvaris reports Q3 results

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on PHVS stock, giving a Buy rating yesterday. Joseph Schwartz has give...

Pharvaris's Strategic Progress in HAE Pipeline Drives Buy Rating and $30 Price Target

STVN

Press Releases

Pharvaris Presents Data at the Bradykinin Symposium 2024

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Pharvaris to Host Virtual Investor Event on October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Axonis Therapeutics Announces $115 Million Series A Financing

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Comments

Pharvaris

Pharvaris (PHVS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga